Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample
-
Published:2024-09-05
Issue:
Volume:
Page:
-
ISSN:0010-3853
-
Container-title:Community Mental Health Journal
-
language:en
-
Short-container-title:Community Ment Health J
Author:
Victor Grant,Kheibari A.,Strickland J. C.
Abstract
AbstractGiven the effectiveness of medication for opioid use disorder (MOUD) and low engagement of treatment among people who use drugs (PWUD), it is important to better understand how to engage treatment clients with MOUD care. The current study aimed to achieve this goal by using qualitative methodology to characterize the MOUD treatment experiences. Participants (N = 52) were recruited for an online semi-structured interview. Qualitative analysis revealed varied treatment experiences, with the majority expressing irregular and intermittent MOUD treatment engagement. The therapeutic effects of MOUD in curbing withdrawal symptoms in conjunction with counseling services was frequently mentioned, as well as a preference for methadone maintenance treatment (MMT) to buprenorphine or naltrexone. Many participants described barriers to treatment and continuation of care, including failed drug screens for non-opioid drugs, perceived stigma, and physician-initiated discontinuation of treatment. The current study revealed that patients had favorable experiences with MOUD treatment, particularly when supplemented with counseling services.
Funder
University of Kentucky College of Social Work National Institute on Drug Abuse
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Andraka-Christou, B., Randall-Kosich, O., & Totaram, R. (2021). Designing an “ideal” substance use disorder treatment center: Perspectives of people who have utilized medications for opioid use disorder. Qualitative Health Research, 31(3), 512–522. https://doi.org/10.1177/1049732320971231 2. Askari, M. S., Martins, S. S., & Mauro, P. M. (2020). Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016. Journal of Substance Abuse Treatment, 114, 108028. https://doi.org/10.1016/j.jsat.2020.108028 3. Austin, A. E., Tang, L., Kim, J. Y., Allen, L., Barnes, A. J., Chang, C. H., Clark, S., Cole, E. S., Durrance, C. P., Donohue, J. M., Gordon, A. J., Huskamp, H. A., McDuffie, M. J., Mehrotra, A., Mohamoud, S., Talbert, J., Ahrens, K. A., Applegate, M., Hammerslag, L. R., & Burns, M. E. (2023). Trends in use of medication to treat opioid use disorder during the COVID-19 pandemic in 10 state Medicaid programs. JAMA Health Forum, 4(6), e231422–e231422. https://doi.org/10.1001/jamahealthforum.2023.1422 4. Barsky, B. A., Mehrotra, A., & Huskamp, H. A. (2023). State policies could impede new efforts to increase access to medications for opioid use disorder. JAMA Health Forum, 4(3), e230071. https://doi.org/10.1001/jamahealthforum.2023.0071 5. Bassuk, E. L., Hanson, J., Greene, R. N., Richard, M., & Laudet, A. (2016). Peer-delivered recovery support services for addictions in the United States: A systematic review. Journal of Substance Abuse Treatment, 63, 1–9. https://doi.org/10.1016/j.jsat.2016.01.003
|
|